Medicare Enrolled
Dr. Leonid Kleynberg, M.D.
Hematology & Oncology · Los Angeles, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kleynberg from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kleynberg?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kleynberg
Dr. Leonid Kleynberg is a hematology & oncology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kleynberg performed 109,520 Medicare services across 2,856 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kleynberg received a total of $13,681 from 80 pharmaceutical and/or device companies across 707 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kleynberg is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 6% volume in CA
$13,681 industry payments
Medicare Practice Summary
Medicare Utilization ↗109,520
Medicare services
Top 6% in CA for hematology & oncology
2,856
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,764 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection, 1 microgram An injection of filgrastim, a medication that stimulates the production of white blood cells. This code specifically covers the brand-name drug and excludes biosimilar versions. |
38,100 | $1 | $1 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
15,108 | $11 | $27 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
7,722 | $1 | $1 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
6,440 | $1 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
5,815 | $0 | $6 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
4,964 | $5 | $5 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
4,628 | $1 | $14 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
4,185 | $58 | $127 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
4,027 | $77 | $116 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
3,237 | $14 | $40 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,780 | $1 | $46 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
2,122 | $18 | $38 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
1,816 | $1 | $7 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
1,716 | $26 | $58 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
1,400 | $0 | $14 |
| Iron dextran injection, 50 mg An injection containing 50 mg of iron dextran administered to the patient. |
1,205 | $13 | $22 |
| Albumin infusion, 5%, 50 ml Administration of a 50 ml intravenous infusion of 5% human albumin solution. |
1,144 | $8 | $100 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
612 | $25 | $55 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
568 | $95 | $171 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
555 | $49 | $70 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
431 | $12 | $40 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
257 | $121 | $264 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
130 | $6 | $103 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
126 | $30 | $102 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
125 | $1 | $8 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
112 | $91 | $157 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
97 | $59 | $130 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
38 | $87 | $172 |
| New patient office visit, 15-29 minutes An initial office visit for a new patient lasting 15 to 29 minutes. This code is used when the total time spent on the date of the encounter meets this duration threshold. |
34 | $60 | $120 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
26 | $143 | $261 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
21.7% high complexity
50.8% medium
27.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,681
Total received (2018-2024)
Avg $1,954/year across 7 years
Top 27% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
80
Companies
707
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,681 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,036
2023
$1,343
2022
$2,127
2021
$2,860
2020
$1,794
2019
$1,683
2018
$2,837
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$236
Spectrum Pharmaceuticals Inc.
$136
Incyte Corporation
$91
Janssen Pharmaceuticals, Inc
$52
SOBI, INC
$47
PharmaEssentia USA Corporation
$47
Novartis Pharmaceuticals Corporation
$45
Daiichi Sankyo Inc.
$43
Celgene Corporation
$39
PFIZER INC.
$37
JAZZ PHARMACEUTICALS INC.
$33
Takeda Pharmaceuticals U.S.A., Inc.
$30
Ipsen Biopharmaceuticals, Inc
$30
Genmab U.S., Inc.
$26
E.R. Squibb & Sons, L.L.C.
$26
TerSera Therapeutics LLC
$25
Amneal Pharmaceuticals LLC
$25
ADC Therapeutics America, Inc.
$24
SUN PHARMACEUTICAL INDUSTRIES INC.
$24
Bayer Healthcare Pharmaceuticals Inc.
$20
Top 3 companies account for 44.6% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,679
Incyte Corporation
$1,576
Amgen Inc.
$1,088
Janssen Biotech, Inc.
$966
PFIZER INC.
$755
Merck Sharp & Dohme Corporation
$582
Novartis Pharmaceuticals Corporation
$533
AstraZeneca Pharmaceuticals LP
$494
Genentech USA, Inc.
$424
Takeda Pharmaceuticals U.S.A., Inc.
$388
Seattle Genetics, Inc.
$287
Bayer HealthCare Pharmaceuticals Inc.
$272
CTI BioPharma Corp.
$208
GENZYME CORPORATION
$207
TerSera Therapeutics LLC
$187
Alexion Pharmaceuticals, Inc.
$187
Eisai Inc.
$169
Karyopharm Therapeutics Inc.
$164
Spectrum Pharmaceuticals Inc.
$155
Bayer Healthcare Pharmaceuticals Inc.
$140
Seagen Inc.
$134
JAZZ PHARMACEUTICALS INC.
$126
GlaxoSmithKline, LLC.
$124
Kite Pharma, Inc.
$123
Gilead Sciences, Inc.
$120
PharmaEssentia USA Corporation
$111
Dova Pharmaceuticals
$104
Ipsen Biopharmaceuticals, Inc
$102
Octapharma USA, Inc.
$96
EISAI INC.
$95
Teva Pharmaceuticals USA, Inc.
$93
Celgene Corporation
$86
Taiho Oncology, Inc.
$85
Lilly USA, LLC
$84
PUMA BIOTECHNOLOGY, INC.
$80
Daiichi Sankyo Inc.
$79
ADC Therapeutics America, Inc.
$79
Shionogi Inc
$73
Genmab U.S., Inc.
$73
Janssen Pharmaceuticals, Inc
$70
GE HEALTHCARE
$70
TOLMAR Pharmaceuticals, Inc.
$61
Merck Sharp & Dohme LLC
$61
Global Blood Therapeutics, Inc.
$61
Mylan Institutional Inc.
$60
Puma Biotechnology, Inc.
$58
Myriad Genetic Laboratories, Inc.
$54
Regeneron Healthcare Solutions, Inc.
$49
SOBI, INC
$47
Jazz Pharmaceuticals Inc.
$46
EMD Serono, Inc.
$45
Amneal Pharmaceuticals LLC
$43
Rigel Pharmaceuticals, Inc.
$42
Foundation Medicine, Inc.
$38
Helsinn Therapeutics (U.S.), Inc.
$38
Coherus Biosciences Inc.
$37
Sirtex Medical Inc
$35
Pharmacyclics LLC, An AbbVie Company
$34
EUSA Pharma (US) LLC
$29
Exelixis Inc.
$25
SUN PHARMACEUTICAL INDUSTRIES INC.
$24
Chiesi USA, Inc.
$23
Progenics Pharmaceuticals, Inc.
$21
Organon LLC
$20
Heron Therapeutics, Inc.
$20
Partner Therapeutics, Inc.
$20
Clovis Oncology, Inc.
$18
Sobi, Inc
$18
Cumberland Pharmaceuticals, Inc.
$18
Stemline Therapeutics Inc.
$17
Biohaven Pharmaceuticals, Inc.
$17
Mirati Therapeutics, Inc.
$16
Shire North American Group Inc
$16
Horizon Pharma plc
$16
Dendreon Pharmaceuticals LLC
$16
ARRAY BIOPHARMA INC
$15
Alnylam Pharmaceuticals Inc.
$15
Emmaus Medical, Inc.
$14
Acrotech Biopharma LLC
$14
Verastem, Inc.
$14
Top 3 companies account for 31.7% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALUNBRIG · AVASTIN · Alecensa · Aliqopa · Aranesp · Avastin · BALVERSA · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · Balversa · Bavencio · Blincyto · CABLIVI · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · ENHERTU · ERBITUX · ERLEADA · Endari · Enhertu · Epkinly · FERRIPROX · FOUNDATIONONE · Fabhalta · Fulphila · GAMIFANT · GAUCHER-DISEASE · GAZYVA · GIVLAARI · HEMADY · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEMPERLI · KANJINTI · KEYTRUDA · KRAZATI · KRYSTEXXA · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MEKINIST · MONJUVI · MVASI · MYCHOICE CDX · Mulpleta · NERLYNX · NINLARO · NURTEC ODT · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONTRUZANT · OPDIVO · OPDUALAG · OXBRYTA · Ogivri · Onivyde · Orserdu · PANZYGA · PEMAZYRE · PIQRAY · PROMACTA · PROVENGE · PYLARIFY · Quzyttir · REBLOZYL · RETACRIT · ROLVEDON · RYBREVANT · Revlimid · Rituxan Hycela · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUSTOL · Stivarga · Sylvant · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Trodelvy · Udenyca · VONJO · VYXEOS · Vectibix · Vonjo · XALKORI · XARELTO · XPOVIO · XYNTHA · Xermelo · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · ZYKADIA · ZYTIGA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
395
Per 100K population
4.0
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kleynberg is a mixed practice specialist, with above-average Medicare volume (top 6% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kleynberg experienced with filgrastim injection, 1 microgram?
Based on Medicare claims data, Dr. Kleynberg performed 38,100 filgrastim injection, 1 microgram services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kleynberg receive payments from pharmaceutical companies?
Yes. Dr. Kleynberg received a total of $13,681 from 80 companies across 707 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kleynberg's costs compare to other hematology & oncology specialists in Los Angeles?
Dr. Kleynberg's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kleynberg) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Los Angeles
Browse hematology & oncology specialists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology